<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> (<z:chebi fb="0" ids="48432">Ang II</z:chebi>) regulates cerebral blood flow by stimulating cerebral vasoconstriction via AT1-receptors </plain></SENT>
<SENT sid="1" pm="."><plain>In adult spontaneously hypertensive rats (SHR), the cerebrovascular autoregulatory curve is shifted to the right, in the direction of higher blood pressures, an indication of excessive cerebrovascular vasoconstriction </plain></SENT>
<SENT sid="2" pm="."><plain>A restricted capacity to dilate cerebral blood vessels may be responsible for the enhanced vulnerability to cerebrovascular <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> during <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We found that <z:hpo ids='HP_0011010'>chronic</z:hpo> treatment with the AT1-receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, <z:chebi fb="0" ids="3347">candesartan</z:chebi>, (0.5 mg/kg/day for 14 days, via osmotic minipumps implanted in the subcutaneous tissue) blocked <z:chebi fb="0" ids="48432">Ang II</z:chebi> binding to AT1-receptors in cerebral blood vessels and in brain areas involved in the regulation of cerebrovascular flow, and increased the ratio of lumen-wall area in the middle cerebral artery </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> treatment normalised the lower part of the autoregulatory curve in SHR, and markedly decreased <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> as a consequence of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> with reperfusion </plain></SENT>
<SENT sid="5" pm="."><plain>Protection from <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> is related to arterial remodelling, enhanced compensatory vasodilatation in the peripheral area of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e>, <z:mp ids='MP_0003188'>decreased reduction</z:mp> in cerebral blood flow following the occlusion of a major cerebral blood vessel, and protection from injury in the periphery of the lesion </plain></SENT>
<SENT sid="6" pm="."><plain>Our results indicate that pre-treatment with AT1-<z:chebi fb="68" ids="48706">antagonists</z:chebi> such as <z:chebi fb="0" ids="3347">candesartan</z:chebi> could be of benefit in the prevention and treatment of brain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischaemia</z:e> </plain></SENT>
</text></document>